{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:29:53Z","timestamp":1788348593875,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejim.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,6,2]],"date-time":"2013-06-02T14:15:37Z","timestamp":1370182537000},"page":"486-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies"],"prefix":"10.1016","volume":"24","author":[{"given":"Spero R.","family":"Cataland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng M.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.05.007_bb0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1538-7836.2003.00169.x","article-title":"Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes","volume":"1","author":"Tsai","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2013.05.007_bb0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.05.007_bb0015","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.05.007_bb0020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/01.ASN.0000060805.04118.4C","article-title":"Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Tsai","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic\u2013uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.05.007_bb0030","first-page":"3303","article-title":"Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) previously receiving chronic plasma exchange\/infusion (PE\/PI): extension study results","volume":"118","author":"Licht","year":"2011"},{"key":"10.1016\/j.ejim.2013.05.007_bb0035","first-page":"193","article-title":"Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange\/infusion (PE\/PI): results of an extension study","volume":"118","author":"Greenbaum","year":"2011"},{"key":"10.1016\/j.ejim.2013.05.007_bb0040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.1538-7836.2003.00170.x","article-title":"Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No","volume":"1","author":"Remuzzi","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2013.05.007_bb0045","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.05.007_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.md.0000133622.03370.07","article-title":"Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement","volume":"83","author":"Coppo","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2013.05.007_bb0055","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.05.007_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-011-0771-5","article-title":"Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience","volume":"93","author":"Jang","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0065","doi-asserted-by":"crossref","first-page":"e33029","DOI":"10.1371\/journal.pone.0033029","article-title":"Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan","volume":"7","author":"Matsumoto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2013.05.007_bb0070","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2013.05.007_bb0075","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0080","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0085","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0090","article-title":"Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis","author":"Povey","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-012-1615-y","article-title":"Profound neurological injury in a patient with atypical hemolytic uremic syndrome","volume":"92","author":"Salem","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0100","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.05.007_bb0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2012.09032.x","article-title":"The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies","volume":"157","author":"Cataland","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0110","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2013uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.05.007_bb0115","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2001-12-0166","article-title":"von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"100","author":"Remuzzi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2013.05.007_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2011.051433","article-title":"Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura","volume":"97","author":"Froehlich-Zahnd","year":"2012","journal-title":"Haematology"},{"key":"10.1016\/j.ejim.2013.05.007_bb0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1537-2995.2004.00626.x","article-title":"Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients","volume":"44","author":"Raife","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.ejim.2013.05.007_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ejim.2013.05.007_bb0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.05.007_bb0140","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejim.2013.05.007_bb0145","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"Reti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2013.05.007_bb0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T07:35:34Z","timestamp":1563089734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0953620513001350"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.05.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}